Immunosyn CEO Hid FDA Hold From Investors, Jury Told
The CEO of publicly traded biopharmaceutical company Immunosyn Corp. hid regulators' concerns about the company's only drug from investors in an effort to keep its stock price high, the U.S. Securities...To view the full article, register now.
Already a subscriber? Click here to view full article